Real-World Management of Pharmacological Thromboprophylactic Strategies for COVID-19 Patients in Japan
Hiroya Hayashi(Metropolitan University), Yugo Yamashita(Kyoto University Hospital), Junichi Nakamura(Hokkaido University Hospital), Makoto Mo(Yokohama Minami Kyosai Hospital), Satoshi Ikeda(Nagasaki University), Hiroko Nakata(Naval Hospital Yokosuka Japan), Eriko Iwata, Fumiaki Wakita(Osaka Metropolitan University), Naoto Yamamoto(Kanagawa Prefectural Hospital Organization), Ichizo Tsujino(Hokkaido University), Makoto Takeyama(Tokyo Yamate Medical Center), Takao Kobayashi(Hokkaido University), Michihisa Umetsu(Tohoku University Hospital), Shizu Aikawa(Cincinnati Children's Hospital Medical Center), Yoshinori Okuno(Kyoto University Hospital), Yoshito Ogihara(Mie University), Nobutaka Ikeda(Toho University), Yuji Nishimoto(Hyogo Prefectural Amagasaki General Medical Center), Daiju Fukuda(Osaka Metropolitan University), Yasumitsu Mizobata(Osaka Metropolitan University), Akane Kondo(Shikoku Medical Center for Children and Adults), Yasuhiro Izumiya(Kumamoto University), Tomohiro Ogawa(International Society of Nephrology), Norikazu Yamada(Tohoku University), Hiromichi Fujii(Osaka Hospital), Sen Yachi(Tokyo Yamate Medical Center), Hirono Satokawa(Fukushima Medical University), Takehisa Iwai(Tokyo Medical and Dental University)
Cited by 9
Related Papers
IL-33–Responsive Lineage−CD25+CD44hi Lymphoid Cells Mediate Innate Type 2 Immunity and Allergic Inflammation in the Lungs
|The Journal of Immunology|2011|552
The Danger Signal, Extracellular ATP, Is a Sensor for an Airborne Allergen and Triggers IL-33 Release and Innate Th2-Type Responses
|The Journal of Immunology|2011|490
IL-33–activated dendritic cells induce an atypical TH2-type response
|Journal of Allergy and Clinical Immunology|2009|400
Association between the abnormal expression of matrix‐degrading enzymes by human osteoarthritic chondrocytes and demethylation of specific CpG sites in the promoter regions
|Arthritis & Rheumatism|2005|349
Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension
|Circulation Cardiovascular Quality and Outcomes|2017|336